ClinicalTrials.gg
Enrolling by invitationNCT07299123Updated Jun 23, 2026

Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA

A Phase 1/2 interventional study of 3D hypoxia-preconditioned UC-MSC group and 2D UC-MSC group in Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Refractory and Severe Aplastic Anemia, sponsored by Chinese PLA General Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 6 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Chinese PLA General Hospital · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Aug 2022, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
6 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 89 studies in Anemia, Aplastic with a site in China — 40 open to participants now, 44 under way, 1 of them phase 3. Anemia, Aplastic · China.

Planned enrollment
44th of 74
40 · median 52
Started
2022
with 8 others
Phase 1/2
8 of 89
4 open now
Primary completion
2026-12
later than 19 of 43 live
Registered
78th of 89
by date

Among the 89 studies in Anemia, Aplastic with a site in China, this one is the 44th largest by planned enrollment of the 74 interventional ones that give a count, is one of 9 that started in 2022, is one of 8 in phase 1/2, reaches primary completion later than 19 of the 43 other live ones, and was the 78th registered.

Anemia, Aplastic

373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

40 of the 89 studies in Anemia, Aplastic with a site in China are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.

This study: 6 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Anemia, Aplastic with a site in China, or all of them as a file.
02

Study summary

Efficacy and Safety of Sequential Infusion of Hypoxic 3D-Cultured Umbilical Cord Mesenchymal Stem Cells in Haploidentical Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia: A Multicenter, Randomized, Phase 1 Trial

Read the detailed description

The enrolled patients with an HLA-haploidentical relative for HSCT received the fludarabine (Flu) + cyclophosphamide (Cy) + antithymocyte globulin (ATG) conditioning regimen. For the patients with acute SAA (SAA-I), intravenous administration of 30 mg/(m2 day) of Flu and 500-800 mg/(m2 day) of Cy was performed from days -5 to -2, and 5μg/(kg day) of ATG was administered from days -4 to -1. For the patients with chronic SAA (SAA-II), the same treatment of ATG and Cy was applied as above with the supplement of 0.6 mg/(kg 6 h) of busulfan (BU) from days -8 to -5 prior to transplantation. Donor selection and hematopoietic stem cell mobilization and collection were conducted based on the consensus of The Chinese Society of Hematology regarding indications, conditioning regimens, and donor selection for allogeneic hematopoietic stem cell transplantation. On day 0, HSCs were infused intravenously. Both groups received 5 × 10⁵/kg UC-MSCs at 4 h before HSC infusion. The control group was transfused with conventional 2D-cultured UC-MSCs, whereas the experimental group received 3D hypoxia-preconditioned UC-MSCs. Standard GVHD prophylaxis consisted of mycophenolate mofetil, cyclosporine A, and methotrexate (MTX).

03

Conditions studied

  • Severe Aplastic Anemia (SAA)
  • Severe Aplastic Anemia, Refractory
  • Severe Aplastic Anemia

Browse trials for

Keywords

  • Severe Aplastic Anemia
  • Hematopoietic Stem Cell Transplantation
  • Mesenchymal Stem Cells
04

Who can participate

Ages eligible
6 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

The inclusion criteria were (1) age 6 to 60 years; (2) diagnosis of SAA or very SAA according to the International Aplastic Anemia Study Group[21]; (3) without any severe pulmonary, cardiac, liver, or renal diseases or any active infection; and (4) adequate performance status ( score 0-2). Exclusion Criteria:(1)Age 6 years or > 60 years; (2)Failure to meet the IAASG-defined diagnosis of SAA/vSAA, or confirmed (3)Fanconi anemia, congenital aplastic anemia (e.g., dyskeratosis congenita, Diamond-Blackfan anemia); (4)Presence of severe pulmonary, cardiac, hepatic, or renal insufficiency; Uncontrolled active infection; (5)Eastern Cooperative Oncology Group (ECOG) performance status score ≥ 3.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    3D hypoxia-preconditioned UC-MSC group

    Drug: 3D hypoxia-preconditioned UC-MSC group

  • Active comparator
    2D UC-MSC group

    Drug: 2D UC-MSC group

Interventions

  • Drug3D hypoxia-preconditioned UC-MSC group

    5 × 10⁵/kg 3D hypoxia-preconditioned UC-MSCs at 4 h before HSC infusion

  • Drug2D UC-MSC group

    5 × 10⁵/kg 2D UC-MSCs at 4 h before HSC infusion

06

What researchers measure

Primary outcomes

  1. Adverse events

    Time frame: The incidence and severity of adverse events (AEs) within the first 150 days after haplo-HSCT

Secondary outcomes

  1. acute GVHD

    Time frame: 100days after HSCT

  2. chronic GVHD

    Time frame: 1 years after HSCT

  3. Surivial

    Time frame: 1 year after HSCT

  4. Rates of relapse

    Time frame: UP to 2 years after HSCT

  5. The implantation

    The implantation rate and implantation time.

    Time frame: Up to 4 weeks after HSCT

07

Study locations

1 site
  • 28 Fuxing Road, Beijing, China.
    Beijing, 100853, China
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Treatment effect

Supporting information: Study protocol

Time frame: 2025/10/1-2027/1/1

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for Dec 2026, 52 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Dec 23, 2025
StartActual
Aug 1, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07299123
Collaborators
Fourth Medical Center of PLA General Hospital, Beijing 302 Hospital, The First Medical Center of Chinese PLA General Hospital, Pollon Life Co., Ltd., Yan'an University Affiliated Hospital, The University of Hong Kong-Shenzhen Hospital, Beijing Friendship Hospital, Beijing GeniusCure Biotechnology Co., Ltd., Shenzhen University General Hospital
Responsible party
Jian Bo (Chief Physician / Associate Professor, Chinese PLA General Hospital) — Principal investigator
First posted
Dec 23, 2025
Start date
Aug 1, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion